A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT03069365

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
  • AbbVie Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03069365
  • EudraCT 2016-004182-60
Other papers using this trial's data
  • Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection Liver international : official journal of the International Association for the Study of the Liver, 2020-05 DOI, PubMed 31821716

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Germany, Greece, Italy, Poland, Puerto Rico, South Korea, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03069365. Non-randomized; no masking; primary purpose treatment. Start 2017-03-28 (actual); primary completion 2018-02-20 (actual). Results posted on 2019-03-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Acronym
EXPEDITION-5
Condition
Hepatitis C Virus (HCV)
Intervention (Drug)
Glecaprevir/pibrentasvir
Lead sponsor
AbbVie (class: industry)

Record details

Record id
cardio:ct-nct03069365
Content hash
426d746f2685754e24e41d14e893eca4c575d9cb8dc5a37febdadbd79fbb6ceb